This startup licenses antibiotic development projects to combat antimicrobial resistance by collaborating with scientists and organizations. By facilitating funding and project development, the company enables the creation of new treatments to address the growing threat of resistant infections globally.
Funding
$810K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The rise of antimicrobial resistance (AMR) poses a significant threat to global health, with a growing number of infections becoming increasingly difficult and costly to treat. The current pipeline of new antibiotics is insufficient to combat the emergence of resistant bacteria, particularly gram-negative pathogens. This lack of effective treatments could lead to a post-antibiotic era, where common infections become life-threatening.
Solution
T.A.Z. Corporation addresses the global crisis of antimicrobial resistance by licensing and developing promising antibiotic projects. The company collaborates with scientists and organizations to provide funding and expertise necessary to advance these projects through preclinical and clinical development. T.A.Z. Corporation focuses on developing treatments effective against ESKAPE organisms, a group of highly resistant pathogens prioritized by the World Health Organization (WHO). By expediting the development of new antibiotics, T.A.Z. Corporation aims to contribute to the fight against antibiotic resistance and improve patient outcomes. Their lead project is a patented antibiotic with broad-spectrum antibacterial activity against clinically important bacteria responsible for hospital-acquired and community-acquired infections.
Target Audience
T.A.Z. Corporation primarily targets pharmaceutical companies and healthcare organizations seeking to expand their antibiotic portfolios and address the growing threat of antimicrobial resistance.
Features
- Licenses antibiotic projects with activity against both Gram-positive and Gram-negative bacteria.
- Focuses on developing treatments effective against ESKAPE organisms.
- Lead compounds exhibit broad-spectrum antibacterial activity against highly resistant strains.
- Partners with NAEJA-RGM Pharmaceuticals for discovery and early-stage development.
- Aims to expedite the timeline for taking candidate compounds into clinical trials.